Systemic Amyloidosis Clinical Trial
Official title:
A Study of Bortezomib, Pomalidomide, Dexamethasone in Patients With Systemic AL Amyloidosis
This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed systemic light chain (AL) amyloidosis. Approximately 40 subjects will receive therapy with bortezomib, pomalidomide, and dexamethasone. The primary outcome is hematologic very good partial response and complete response rate at 6 months.
Proteasome inhibitor and immunmodulators have synergistic effect for plasma cell dyscrasia. Due to the fact that more than 70-80% of patients with amyloidosis have renal involvement, the application of lenalidomide is limited. Thus, the investigators designed this open-label, multicenter, phase 2 study for newly diagnosed or previously treated systemic AL amyloidosis with bortezomib, pomalidomide and dexamethasone regimen. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03678259 -
124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04006223 -
The Diagnostic Value of Hybrid PET/MR for Systemic Amyloidosis
|
||
| Recruiting |
NCT05951816 -
A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
|
Phase 1 | |
| Recruiting |
NCT06186167 -
Amyloidosis Incidence in High-Risk Cardiac Device Patients
|
||
| Recruiting |
NCT05150353 -
Detection of Amyloid Deposits in the Wrist by MRI With Mapping and High Resolution Sequences in Systemic Amyloidosis (AMYLOCARP)
|
N/A | |
| Active, not recruiting |
NCT05968846 -
Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load
|
Phase 2 |